<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822730</url>
  </required_header>
  <id_info>
    <org_study_id>100000-068943</org_study_id>
    <nct_id>NCT01822730</nct_id>
  </id_info>
  <brief_title>A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis</brief_title>
  <official_title>A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Hao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or
      environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical
      presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),
      response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic
      neurotransmission) of both conditions. Both paliperidone and risperidone are second
      generation antipsychoticsï¼Œbut have same pharmacological effects of antipsychotic treatment
      and paliperidone may have more efficacy and safty.This study was designed to examine the
      acute efficacy, safety, and tolerability of paliperidone and risperidone for patients with
      MAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:A Multiple-Center, Randomized, Double-Blind.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The severity of psychosis</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <description>Positive and Negative Syndrome Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical general status</measure>
    <time_frame>up to 4 weeks. participants will be followed for the duration of hospital stay</time_frame>
    <description>Clinical general rating scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>paliperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>.Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone</intervention_name>
    <description>Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>paliperidone</arm_group_label>
    <other_name>Paliperidone Extended-Release Tablets</other_name>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks</description>
    <arm_group_label>.Risperidone</arm_group_label>
    <other_name>Risperdal H20070057</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)
             criteria for Methamphetamine-Associated Psychosis.

          2. Must sign a Information consent form.

          3. Required to provide detailed address and phone number

        Exclusion Criteria:

          1. Serious organic disease.

          2. Suicide ideation or hurt others.

          3. Taking antipsychotic within two weeks before.

          4. drug allergy to Risperidone or paliperidone.

          5. pregnancy and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Hao, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Wei Hao</investigator_full_name>
    <investigator_title>The Second Xiangya Hospital of Cental South University</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine-Associated Psychosis</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

